Table 1.
Baseline Characteristics of the HIV ECs, HIV-Suppressed, and HIV-Uninfected Patient Cohortsa
| Variable | ECs (N = 42) | Suppressed (N = 80) | Uninfected (N = 43) | P Value |
|---|---|---|---|---|
| Age (years) | 49 [45–55] | 49 [45–53] | 49 [44–51] | .78 |
| Gender (%male) | 81% | 69% | 67% | .31 |
| Race | .16 | |||
| White (%) | 74% | 56% | 53% | |
| Black (%) | 19% | 36% | 40% | |
| Other (%) | 2% | 6% | 7% | |
| Unknown (%) | 5% | 1% | 0% | |
| CD4+ count (cells/µL) | 807 [690–1043] | 534 [357–762] | <.01 | |
| Duration of HIV infection (years) | 16 [10–20] | 15 [10–20] | .64 | |
| Duration of ART (years) | 9 [5–12] |
Bolded P value represents statistical significance.
Abbreviations: ART, antiretroviral therapy; ECs, elite controllers; HIV, human immunodeficiency virus.
a Significance testing by Kruskal-Wallis, Wilcoxon rank-sum, or χ2 tests. Reported values are median [Q1–Q3] or percentages.